OMNIAB, INC. Debt Securities, Available-for-sale, Gain (Loss)
OMNIAB, INC. (OABI) reported Debt Securities, Available-for-sale, Gain (Loss) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleGainLoss · last filed 2023-03-30
- OMNIAB, INC. debt securities, available-for-sale, gain (loss) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- OMNIAB, INC. debt securities, available-for-sale, gain (loss) for fiscal 2021 was $1.26M.
| Period end | Debt Securities, Available-for-sale, Gain (Loss) 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-30 |
| 2021-12-31 | $1.26M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |